MERIAL LLC – Trademark Portfolio

Entity Type: 16

MERIAL LLC holds 25 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 24 filings in this category. The portfolio also extends into Class 31 (Natural Agricultural Products) across 2 Nice Classification classes. Currently, 10 trademarks are registered. Notable registered marks include CORID, IVOMEC, EPRINEX, EQVALAN, and CURATREM. The owner is based in DULUTH, GA.

3239 SATELLITE BOULEVARD

DULUTH, GA 30096

25 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Page 1 of 2 (25 results)

Trademark Classifications

MERIAL LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (24 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

31
Natural Agricultural Products (1 filing)

Raw and unprocessed agricultural, aquacultural, horticultural and forestry products

Frequently Asked Questions

How many trademarks does MERIAL LLC have?

MERIAL LLC has 25 U.S. trademarks filed with the USPTO. Of these, 10 registered, 4 abandoned, 11 cancelled.

What trademark classes does MERIAL LLC file in?

MERIAL LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 31 (Natural Agricultural Products). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are MERIAL LLC's most well-known trademarks?

MERIAL LLC's registered trademark portfolio includes well-known marks such as CORID, IVOMEC, EPRINEX, EQVALAN, and CURATREM. These are among 10 currently registered trademarks in the portfolio.

What is MERIAL LLC's trademark registration success rate?

MERIAL LLC has a 40% trademark registration rate, with 10 out of 25 resolved applications resulting in successful registration. Currently, 0 applications are pending review.